Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3034701 in Overweight / Obesity
NCT07754474Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3034701 in obesity (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-Emergent Adverse Events at 113 days. Started Sep 2026; status: recruiting.
02
Drugs
BI 3034701
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07754474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07754474.